Author

Patricia Kropf

Associate Professor, Fox Chase Cancer Center - Cited by 2,445 - Acute Leukemia

Biography

Dr. Patricia L. Kropf is an oncologist in Charlotte, North Carolina. She received her medical degree from Georgetown University School of Medicine and has been in practice between 11-20 years.
Title
Cited by
Year
Functional genomic landscape of acute myeloid leukaemia
JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ...Nature 562 (7728), 526-531, 2018201
876
2018
DNA hypomethylating drugs in cancer therapy
T Sato, JPJ Issa, P KropfCold Spring Harbor perspectives in medicine 7 (5), 2017201
118
2017
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
G Garcia-Manero, G Roboz, K Walsh, H Kantarjian, E Ritchie, P Kropf, ...The Lancet Haematology 6 (6), e317-e327, 2019201
75
2019
Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology
R Mesa, C Jamieson, R Bhatia, MW Deininger, AT Gerds, I Gojo, J Gotlib, ...Journal of the National Comprehensive Cancer Network 14 (12), 1572-1611, 2016201
68
2016
NCCN guidelines insights: chronic myeloid leukemia, version 1.2017
A Pallera, JK Altman, E Berman, CN Abboud, B Bhatnagar, P Curtin, ...Journal of the National Comprehensive Cancer Network 14 (12), 1505-1512, 2016201
68
2016
Splenic irradiation for splenomegaly: A systematic review
NG Zaorsky, GR Williams, SK Barta, NF Esnaola, PL Kropf, SB Hayes, ...Cancer treatment reviews 53, 47-52, 2017201
36
2017
Chimeric antigen receptor T-cell therapy
N Ogba, NM Arwood, NL Bartlett, M Bloom, P Brown, C Brown, EL Budde, ...Journal of the National Comprehensive Cancer Network 16 (9), 1092-1106, 2018201
21
2018
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
W Chung, AD Kelly, P Kropf, H Fung, J Jelinek, XY Su, GJ Roboz, ...Clinical epigenetics 11 (1), 1-12, 202
19
2019
S879 Results of ASTRAL-1 study, a phase 3 randomized trial of guadecitabine (G) vs treatment choice (TC) in treatment naïve acute myeloid leukemia (TN-AML) not eligible for …
P Fenaux, M Gobbi, PL Kropf, J Mayer, GJ Roboz, H Döhner, J Krauter, ...HemaSphere 3 (S1), 394-395, 2019201
18
2019
Results from a global randomized phase 3 study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naive (TN) AML Unfit for Intensive Chemotherapy (IC …
GJ Roboz, H Döhner, M Gobbi, PL Kropf, J Mayer, J Krauter, T Robak, ...Blood 134, 2591, 2019201
16
2019
Long term results of a randomized phase 2 dose-response study of guadecitabine, a novel subcutaneous (SC) hypomethylating agent (HMA), in 102 patients with intermediate or high …
G Garcia-Manero, EK Ritchie, KJ Walsh, MR Savona, HM Kantarjian, ...Blood 2, 231, 2018201
13
2018
A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia
RL Redner, JH Beumer, P Kropf, M Agha, M Boyiadzis, K Dorritie, R Farah, ...Leukemia & lymphoma 5 (11), 255-2601, 2018201
9
2018
Donor lymphocyte infusion in hematologic malignancies—good to be fresh?
NM Hossain, T Klumpp, J Ulicny, M Garner, PL Kropf, KF Mangan, ...Clinical Lymphoma Myeloma and Leukemia 16 (2), 111-115, 2016201
7
2016
Demethylator phenotypes in acute myeloid leukemia
AD Kelly, J Madzo, P Madireddi, P Kropf, CR Good, J Jelinek, JPJ IssaLeukemia 32 (10), 2178-2188, 2018201
6
2018
Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia
P Kropf, G Barnes, B Tang, A Pathak, JPJ IssaLeukemia & Lymphoma 57 (), 935-91, 2016201
4
2016
CMV and BK virus reactivation in post transplant cyclophosphamide (PTCY) after allogeneic MUD, MRD and haploidentical transplant
TP Wang, M Sochat, CRC Tan, NM Hossain, J Ulicny, PA Pancari, ...Biology of Blood and Marrow Transplantation 3 (3), S305-S306, 01701
2
2017
Improved survival for MDS/CMML patients treated with the combination of decitabine (DAC) and arsenic trioxide (ATO) in a phase II adaptive three arm randomization study: DAC …
PL Kropf, R Shameem, PA Pancari, H Fung, L Xiao, X Huang, W Chung, ...Blood 18 (), 3170, 01601
2
2016
Abstract CT321: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not …
Abstract CT31: First results of a 10-day regimen of SGI-110 (guadecitabine), a second generation hypomethylating agent (HMA) in previously untreated elderly AML who are not …G Roboz, H Kantarjian, P Kropf, E Richie, N Jain, E Griffiths, NA Podoltsev, ...Cancer Research 75 (15_Supplement), CT31-CT31, 01501
2
2015
Multivariate analysis identifies significant correlations between baseline biomarkers, DNA demethylation and clinical responses in 122 patients treated in a phase 1/2, study of …
Multivariate analysis identifies significant correlations between baseline biomarkers, DNA demethylation and clinical responses in 1 patients treated in a phase 1/, study of …S Gottipati, S Rohatagi, W Chung, P Taverna, HM Kantarjian, GJ Roboz, ...Blood 16 (3), 594, 01501
2
2015
Epigenetics and epigenetic therapy of cancer
O Fasan, P Boland, P Kropf, JPJ IssaTargeted therapy in translational cancer research, 7-79, 01501
2
2015

Referred From: https://scholar.google.com/citations?user=MwD3lhYAAAAJ&hl=en

Cited by
Citations 2445
h-index 18
i10-index 27
Recommended Journals
Open Access Journals